MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company’s lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ.
Details of the presentations are as follows:
Title:Functional and sexual disability, and quality of life after one dose of MM120 (lysergide) in adults with generalized anxiety disorderFormat: PosterPresenter: Paula Jacobson, Ph.D., Executive Director, Clinical Development, MindMed
Title:Rapid and durable response to a single dose of MM120 (lysergide) in generalized anxiety disorder: A dose-optimization studyFormat: PosterPresenter: Dan Karlin, M.D., M.A., Chief Medical Officer, MindMed
Posters are available on MindMed’s Companywebsite.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
This press release is not sanctioned by ACNP.
View source version on businesswire.com:https://www.businesswire.com/news/home/20241211736280/en/
For Media:media@mindmed.coFor Investors:ir@mindmed.coFor Medical Affairs:medaffairs@mindmed.co
Source: Mind Medicine
Released December 11, 2024